SCHEMBL631338

SCHEMBL631338

FC(F)(F)c1cnccn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.44
CYP19A1 P11511 2/20 0.42
HSP90AA1 P07900 1/20 0.40
LOXL2 Q9Y4K0 2/20 0.38
LOX P28300 1/20 0.36
TSHR P16473 2/20 0.36
ALOX15 P16050 1/20 0.36
CASP1 P29466 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.36
IDO1 P14902 1/20 0.35
KDM4E B2RXH2 3/20 0.34
NAPRT Q6XQN6 1/20 0.34
HCAR2 Q8TDS4 1/20 0.34
CA2 P00918 1/20 0.33
CHKA P35790 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
BAZ2B Q9UIF8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29526853 1.00 TRPV4 (0.44) TRPV4CYP19A1HSP90AA1LOXL2LOX
SCHEMBL18661266 0.83 SMN1; SMN2 (0.37) TRPV4CYP19A1LOXL2LOXTSHR
SCHEMBL28088002 0.82 TSHR (0.35) TRPV4CYP19A1HSP90AA1LOXL2LOX
SCHEMBL28221312 0.82 RAB9A (0.34) TRPV4CYP19A1TSHRALOX15CASP1
SCHEMBL28687790 0.81 CYP19A1 (0.33) TRPV4CYP19A1HSP90AA1LOXL2LOX
SCHEMBL9589700 0.80 CYP19A1 (0.40) TRPV4CYP19A1HSP90AA1TSHRALOX15
SCHEMBL20774860 0.80 CYP19A1 (0.40) TRPV4CYP19A1HSP90AA1TSHRALOX15
Ethoxycarbonyl Group SCHEMBL27906093 0.77 KMT2A (0.34) TRPV4CYP19A1KDM4ENPC1RAB9A
SCHEMBL5720338 0.76 CYP19A1 (0.44) CYP19A1HSP90AA1TSHRKDM4ENAPRT
SCHEMBL22970752 0.75 ALOX15 (0.41) TSHRALOX15CASP1NPSR1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025068347-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2025-04-03 WO claimed
EP-3966210-A1 NOVEL COMPOUNDS GlaxoSmithKline Intellectual Property Development Limited (GB) 2022-03-16 EP claimed
WO-2021118485-A1 A PRODUCTION METHOD OF BIOACTIVE SUBSTANCE THYMOKINONE BY USING AY-YLDIZ CATALYST WHITH USE POTENTIAL IN CANCER TREATMENT CUKUROVA UNIVERSITESI REKTORLUGU (TR) 2021-06-17 WO claimed
US-10224485-B2 Process for preparing a crystalline organic semiconductor material BASF SE (DE) 2019-03-05 US claimed
CN-105358550-B Histone deacetylase inhibitors 卡鲁斯治疗有限公司 2018-04-06 CN claimed
CN-107001389-A Triazolopyrazine radical derivative as soluble guanylate cyclase activators 默沙东公司 2017-08-01 CN claimed
CN-106928247-A Spiral shell oxindole compounds and its purposes as therapeutic agent 泽农医药公司 2017-07-07 CN claimed
CN-106715423-A Amino-substituted isoxazoles 拜耳制药股份公司 2017-05-24 CN claimed
US-20170012208-A1 ORGANIC SEMICONDUCTOR FORMULATIONS USINVEST LLC 2017-01-12 US claimed
CN-104447649-B Methyl naphtho-[1,2-b] amide compounds and pharmaceutically acceptable salt and its preparation method and application thereof 辽宁大学 2016-08-17 CN claimed
CN-103596937-B Substituted benzamide derivatives 霍夫曼-拉罗奇有限公司 2016-06-29 CN claimed
CN-104447649-A Methylnaphtho-[1,2-b] furan amide compound, and pharmaceutical acceptable salt, preparation method and application of methylnaphtho-[1,2-b] furan amide compound UNIV LIAONING 2015-03-25 CN claimed
US-12630533-B2 Heterocyclic compounds useful as KCNT1 inhibitors ACTIO BIOSCIENCES, INC. (US) 2026-05-19 US disclosed
EP-4735431-A2 MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. (US) 2026-05-06 EP disclosed
US-12577239-B2 Sulfilimines or sulfoximines containing fungicidal heterocyclic compounds PI INDUSTRIES LTD. (IN) 2026-03-17 US disclosed
EP-4688154-A1 MORPHOLINE OREXIN RECEPTOR ANTAGONISTS BIAL - Portela & Ca., S.A. (PT) 2026-02-11 EP disclosed
EP-0102542-B1 1,2,4,6-THIATRIAZIN-1,1-DIOXIDE ETHERS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES BASF Aktiengesellschaft (DE) 1990-07-04 EP disclosed
US-4585472-A PRE- AND POSTEMERGENCE HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1986-04-29 US disclosed
EP-0102542-A2 1,2,4,6-Thiatriazin-1,1-dioxide ethers, process for their preparation and their use as herbicides BASF Aktiengesellschaft (DE) 1984-03-14 EP disclosed
US-4081542-A ANOREXIC AGENTS MERCK & CO., INC. (US) 1978-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630533-B2 Heterocyclic compounds useful as KCNT1 inhibitors KCNT1, KCNT2, KCNJ2 TRPV4 360/4885CYP19A1 2531/4885HSP90AA1 3458/4885
US-10224485-B2 Process for preparing a crystalline organic semiconductor material STOM, SPOP, TTR TRPV4 449/4885CYP19A1 1759/4885HSP90AA1 4250/4885
US-12577239-B2 Sulfilimines or sulfoximines containing fungicidal heterocyclic compounds SULT1E1, CBR1, SULT1A1 TRPV4 4529/4885CYP19A1 1565/4885HSP90AA1 1250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.